PharmaTimes | in-depth news, features and insights for the ...
6 days ago · Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020.
News - PharmaTimes
Oct 31, 2024 · NICE recommends remote monitoring technology for heart failure patients. 31st Oct 2024. Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020.
Super models - PharmaTimes
Super models. 24th Oct 2024. Published in PharmaTimes magazine -. by Dr Ben Sidders. A framework to optimise R&D success with AI. The impact of AI/data-driven drug discovery is evolving rapidly in life sciences. Harnessing the beneficial potential of this technology, however, requires its optimal integration into R&D says Biorelate’s Dr Ben ...
PharmaTimes - June 2024
This issue is about the shaping, delivery and future of clinical trials – the exciting dawn of a new era for how therapies reach the marketplace. We cover the influence of digital, the radical shift in trial design and, above all, the need to incorporate patients at every stage. We’ve also got a review of our International Clinical Researcher of the Year bash – an unforgettable 25th ...
Deal or no deal - PharmaTimes
Mar 14, 2024 · Approaches to M&As in pharma points to each company’s philosophy. According to GlobalData’s Q4 2023 update, there were 426 M&A deals announced in the global pharmaceutical industry over the year, worth a total of USD 84.2Bn.
The trials of our lives - PharmaTimes
May 24, 2024 · What a time to be alive. Medicines that allow us go on living healthy lives for longer than ever before already exist. And we know these technologies will only get better over the rest of our lifetimes.
About us - PharmaTimes
Email: [email protected] Telephone: +44 (0)207 2406999. PharmaTimes Media Ltd. Mansard House, Church Road, Little Bookham, Leatherhead, Surrey, KT23 3JG ...
Movers and shakers - PharmaTimes
M&A volumes more than doubled between 2005 and 2019. By comparison, 2020 has been a slow year, with a marked decline in deal activity and a sharp drop in overall deal value. Mega deals have been sparse – last year opened with Bristol-Myers Squibb (BMS) announcing its $74 billion acquisition of Celgene, and Abbvie’s $63 billion bid for ...
Back to pharma’s future - PharmaTimes
Feb 26, 2024 · For those pharma companies still in the UK – after Brexit, COVID, economic turmoil and the ongoing NHS crisis – be assured, the future still holds promise.
PharmaTimes - June 2021
This month’s PharmaTimes is packed with a variety of features centred on clinical research, the lifeblood of our industry. Our insightful front cover article delves into the key regulatory considerations on both sides of the Atlantic for starting cell and gene therapy trials (p26), while others look at the rise of genetic sequencing (p30) and 2021 trends in global trials (p20).